09:35 AM EDT, 10/29/2024 (MT Newswires) -- Grifols ( GRFS ) said Tuesday that its plasma-protein-based fibrin sealant for controlling surgical bleeding has been approved for pediatric patients by the US Food and Drug Administration.

The product, marketed as Vistaseal in the US and Canada by Johnson & Johnson ( JNJ ) MedTech under a collaboration with Grifols ( GRFS ), promotes hemostasis and tissue sealing during surgery, according to Grifols ( GRFS ).

The Spanish biopharmaceutical company said the fibrin sealant was previously approved for adults and children in Europe.

Shares of Grifols ( GRFS ) were up more than 4% and Johnson & Johnson ( JNJ ) added 0.1% in early trading Tuesday.

Price: 8.68, Change: +0.34, Percent Change: +4.08